Among the five patients treated with CD19/CD22 BS Loop CAR-T cells, the main adverse reactions included fever and hematologic toxicity; three patients presented with low-grade fever, one patient developed rash, four patients had thrombocytopenia, and all five patients experienced neutropenia and developed anemia (Supplementary Table S2). This evidence concerns the gene CD22 and anemia (phenotype).